Senti Biosciences, Inc.
2 Corporate Drive, First Floor
South San Francisco, California 94080
August 4, 2022
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance – Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Senti Biosciences, Inc. |
Registration Statement on Form S-1
File No. 333-265873
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Senti Biosciences, Inc. (the “Company”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-265873) (the “Registration Statement”), so that it may become effective at 4:00 pm Eastern time on August 8, 2022, or as soon thereafter as practicable.
| Very truly yours, | ||
| SENTI BIOSCIENCES, INC. | ||
| By: | /s/ Timothy Lu | |
| Name: Timothy Lu | ||
| Title: President & Chief Executive Officer | ||
Cc: Maggie Wong, Goodwin Procter LLP